D000998Chemicals & DrugsD27.505.954.122.38842912260.575788Antiviral AgentsFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonInfectious Diseases, Infection Control, and Employee HealthMD AndersonHARRYS ANTONIOTORRESHARRYS ANTONIO TORRES8947TORRES, HARRYS ANTONIOAssociate ProfessorROY FCHEMALYROY F CHEMALY9024CHEMALY, ROY FProfessor74Professor21Chair14Associate Professortrue1ProfessorProfessor10.42760.00110313429research area of0.9673350.00766346846subject area forDepartment of MedicineMedicine-Gastroenterology & HepatolBaylor College of MedicineJOHNVIERLINGJOHN VIERLING29.70970200000000-95.40162500000000882VIERLING, JOHNProfessorFASIHAKANWALFASIHA KANWAL29.70503200000000-95.407546000000004180KANWAL, FASIHAProfessorHASHEMEL-SERAGHASHEM EL-SERAG29.70560750000000-95.3846773000000068EL-SERAG, HASHEMProfessortrue1ProfessorProfessortrue1ProfessorProfessor36442063Potter GE, Bonnett T, Rubenstein K, Lindholm DA, Rapaka RR, Doernberg SB, Lye DC, Mularski RA, Hynes NA, Kline S, Paules CI, Wolfe CR, Frank MG, Rouphael NG, Deye GA, Sweeney DA, Colombo RE, Davey RT, Mehta AK, Whitaker JA, Castro JG, Amin AN, Colombo CJ, Levine CB, Jain MK, Maves RC, Marconi VC, Grossberg R, Hozayen S, Burgess TH, Atmar RL, Ganesan A, Gomez CA, Benson CA, Lopez de Castilla D, Ahuja N, George SL, Nayak SU, Cohen SH, Lalani T, Short WR, Erdmann N, Tomashek KM, Tebas PAnnals of internal medicineTemporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial. Ann Intern Med. 2022 12; 175(12):1716-1727.Ann Intern Med2022-11-29T00:00:002022Temporal Improvements in COVID-19 Outcomes for Hospitalized Adults: A Post Hoc Observational Study of Remdesivir Group Participants in the Adaptive COVID-19 Treatment Trial.36773622Uraki R, Ito M, Kiso M, Yamayoshi S, Iwatsuki-Horimoto K, Furusawa Y, Sakai-Tagawa Y, Imai M, Koga M, Yamamoto S, Adachi E, Saito M, Tsutsumi T, Otani A, Kikuchi T, Yotsuyanagi H, Halfmann PJ, Pekosz A, Kawaoka YThe Lancet. Infectious diseasesAntiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate. Lancet Infect Dis. 2023 04; 23(4):402-403.Lancet Infect Dis2023-02-08T00:00:002023Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.37247393Zhu H, Ren VJournal of medical virologyAntiviral therapy in DRESS. J Med Virol. 2023 06; 95(6):e28839.J Med Virol2023-06-01T00:00:002023Antiviral therapy in DRESS.37696289Duan Y, Zhou H, Liu X, Iketani S, Lin M, Zhang X, Bian Q, Wang H, Sun H, Hong SJ, Culbertson B, Mohri H, Luck MI, Zhu Y, Liu X, Lu Y, Yang X, Yang K, Sabo Y, Chavez A, Goff SP, Rao Z, Ho DD, Yang HNatureMolecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir. Nature. 2023 Oct; 622(7982):376-382.Nature2023-09-11T00:00:002023Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.37669225Jordan R, Ford-Scheimer SL, Alarcon RM, Atala A, Borenstein JT, Brimacombe KR, Cherry S, Clevers H, Davis MI, Funnell SGP, Gehrke L, Griffith LG, Grossman AC, Hartung T, Ingber DE, Kleinstreuer NC, Kuo CJ, Lee EM, Mummery CL, Pickett TE, Ramani S, Rosado-Olivieri EA, Struble EB, Wan Z, Williams MS, Hall MD, Ferrer M, Markossian SThe Journal of infectious diseasesReport of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development. J Infect Dis. 2023 10 03; 228(Suppl 5):S337-S354.J Infect Dis2023-10-03T00:00:002023Report of the Assay Guidance Workshop on 3-Dimensional Tissue Models for Antiviral Drug Development.true1ProfessorProfessortrue1Associate ProfessorAssociate Professor